Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up    |  Already a member? Sign In
Pharma IQ

Columns

12 column results
   Page  of 2  

  • Anthony Chambers Sustain Your ELN – Before You Start Your ELN: Change management can be found as a bullet under “critical success factors” in many Electronic Lab Notebook project charters. Touted as crucial in determining the success of an ELN, many agree in principle that change management is needed, but don’t know how to go about making it effective, tangible, and measurable. read more
     January 25,2012 by Anthony Chambers   0


  • Cristina Falcão Taxing “Globesity” To Save Our Children: Will “Fat taxes” affect consumption, and eventually obesity? The impact of imposing taxes on the consumption of certain foods depends on the responsiveness of consumers to price changes, i.e. price elasticity. It is difficult to predict how consumers will react to price changes caused by taxation. read more
     March 24,2012 by Cristina Falcão   0


  • Cristina Falcão Big Pharma Cannot Afford to be Lost in Translation: Since more and more clinical research and drug manufacturing are being done in multiple countries and in multiple languages, quality language services can help bring a drug to market faster, and can help streamline the clinical trial process. Translation may be required at many stages, including clinical research, regulatory submission and review, production and marketing. read more
     February 16,2012 by Cristina Falcão   5




  • Jon Wetzel Top 5 things You Need to Know about Inventory: Inventory is one of the primary wastes in lean thinking and is also the hardest for people to change their mindset about. I’ve compiled my list of the top 5 items you need to know in order to understand the downfall of having Inventory laying around. read more
     November 30,2011 by Jon Wetzel   1



  • John Trigg Management Buy-in and User Acceptance in an ELN Project: But the management commitment is also required throughout the implementation phases. Getting the balance right between hands-off and hands-on is critical; too much hands-off, and the project team and users get concerned whether management cares; too much hands-on and it can feel like interference and a lack of trust. read more
     September 12,2011 by John Trigg   0


  • John Trigg Where Do the Ideas Come From?: When it comes to purchasing and implementing laboratory systems’ software, return on investment is inevitably one of the key drivers. The up-front requirements to justify the expenditure are usually aligned to process improvement and productivity often driven by a functional need to work with dispersed teams, across different sites, regions and time zones. But there’s usually a secondary, softer requirement aligned to return on investment, but more difficult to quantify, that alludes to an improvement in knowledge management within the organisation by making laboratory information explicit, accessible and reusable. read more
     June 7,2011 by John Trigg   0



  • Eric Langer Higher Tech Outsourcing Repositions CMOs: While many biomanufacturers continue to view outsourcing as part of their cost reduction approach, more are considering how they can incorporate outsourcing of the technical more complex upstream and downstream operations as part of their business strategy. If biopharma companies hold to these plans, the outsourcing arena may change considerably over the next few years. read more
     September 7,2011 by Eric Langer   0


  • Eric Langer Single Use Bioreactors Lead in New Use and Market Penetration: Single use technologies are strong change agents in biopharma manufacturing. Disposable devices emerge once again as a top new technology of interest among the 352 surveyed biomanufacturers in BioPlan Associates, Inc.’s 2011 8th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production. read more
     August 8,2011 by Eric Langer   0



  • Mollie Shields-Uehling Nobody Knows You’re a Dog: A few years ago, The New Yorker magazine published a cartoon of two dogs sitting in front of a computer monitor. One was explaining to the other: “On the Internet, nobody knows you’re a dog.” Given the regulated nature of the global biopharmaceutical industry, the explosion in global collaboration, and our reliance on the Internet, it is absolutely essential that we know and trust the identity of people on the other side of the screen. read more
     July 13,2011 by Mollie Shields-Uehling   0



  • Elie Magdalani Medication Errors - A Shared Responsibility: We can not separate pharmacovigilance from medication errors, pharmacovigilance had always been concerned with minimizing the risks of adverse drug reactions and medication errors. Pharmacovigilance contributes to the detection and prevention of medication errors, collaboration of all parties will improve the quality of data collected, and enhancing patient safety. A shared responsibility, in detecting Medication Errors depends on the collaboration of the patient, the pharmaceutical companies, the pharmacovigilance centers, and poison control centers. read more
     June 3,2011 by Elie Magdalani   1


  • Elie Magdalani Global Drug Safety and Risk Management: The role of pharmaceutical companies is to decide how to manage the results of an AE signal. Some drug companies develop and prepare the safety programs that are implemented from the moment drugs when enter their product portfolio. Also collecting and analysing data in an advance way is an important tool in drug safety and risk management program. In this concern, whatever the approach selected, each program needs to be reasonably relevant to the nature of the risk. When a signal of a potential side effect is detected it should be documented with its response. read more
     May 6,2011 by Elie Magdalani   1


  • Elie Magdalani Patients Safety and Clinical Trials: Emerging new safety data may result in an action plan by the pharmaceutical company producing a drug to review its data retrieved during the clinical trail phases and especially in Phase II conducted to demonstrate and assess the product’s safety. read more
     February 7,2011 by Elie Magdalani   0

12 column results
   Page  of 2  

Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Top Rated
Most Read